ISOP 2021 Annual Meeting

Relying on combined global, regional and country information in Pharmacovigilance

Relying upon multiple sources of global, regional and country information for signal detection and safety decision making

Dr Richard Hill

November 8 3A-1



Disclaimer and declaration of conflict of interest

Dr Richard Hill Senior Medical Officer, International Regulatory Branch, TGA

Declaration of Conflicts of Interest

No conflict of interest to declare

Disclaimer: The views expressed in this presentation reflect the personal views of the author and do not necessarily reflect the views of the authors' employers (Therapeutic Goods Administration, Australia) nor ISoP, nor any other institutions the author may otherwise be collaborating with.

Contact information:

richard.hill@health.gov.au



Relying upon multiple sources of global, regional and country information for signal detection and safety decision making



1	Relying upon multiple sources of global, regional		
	and country information for signal detection and		
	safety decision making		
2	PV reliance in the Arab world		
3	Experience of a NRA with limited resources using		
	VigiLyze		

November 8 3A-1



In the beginning (2001)

postmarket	VigiBase-VigiSearch
premarket	?



ISoP 2021 Annual Meeting

worldwide







Slide 4

Benefits of international cooperation/reliance

- More reports -> improved signal detection
- Access to expertise & experience
- Reduce duplication of effort
- Reduce evaluation times



Now (2021)

postmarket	VigiBase-VigiLyze ICMRA IPMST
premarket	project ORBIS Access Consortium ASEAN-JACG
RMP/PSUR	Access Consortium



ICMRA

- International Coalition of Medicines Regulatory Authorities
- 24 member agencies and 11 associate members
- Three pharmacovigilance working groups
 - big data
 - increasing AE reporting
 - vaccines
- COVID-19 group meets twice per month



Access Consortium

- Australia-Canada-Singapore-Switzerland-UK
- "Like-minded, medium-sized" regulatory authorities
- Focus on premarket activities
- Work sharing subgroups
 - new active substances
 - generic medicines
 - biosimilars
- COVID-19
- RMPs/PSURs/PBRERs: information sharing (not work sharing)







IPMST

- International Post-Market Surveillance Teleconference
- Australia-USA-Canada-NZ-Singapore-Switzerland-UK
- Every two months
- Sharing of signals under investigation, mainly following local identification



Routine use of external data for PV evaluations at TGA

- Published literature
- International labelling
 - readily available: US, Canada, AUS, UK, EMA
- VigiLyze case numbers; countries; statistics
 - rarely request original reports
 - IPMST (medicines)
 - ICMRA (COVID-19)





Example: vedolizumab-pancreatitis

- vedolizumab used for Crohn's and ulcerative colitis
- 4 Australian reports of pancreatitis (unlisted)
 - detected on routine statistical screening of database (PRR 5.5)
 - 2 good quality published reports
 - VigiBase IC₀₂₅ +0.4
- Discussed with other regulators (IPMST)
 - US FDA: signal under review -> added to 6.3 Postmarketing Experience
 - other regulators: minimal / poor case reports; no review









Local (Australian) programs

- The programs below are funded by the Australian Government Department of Foreign Affairs and Trade
- Pacific Medicines Testing Program (PMTP) launched March 2018
 - Provide Pacific Island Countries access to Australian laboratory testing for medicine quality assurance
- Indo-Pacific Regulatory Strengthening Program (RSP) launched October 2018
 - Strengthen the capabilities of National Regulatory Authorities to increase the availability of better quality, safer and more effective medicines/medical devices through improved regulatory practice and collaboration
- The Australian Expert Technical Assistance Program Regulatory Support and Safety Monitoring (AETAP-RSSM) – launched May 2021
 - Support Pacific and Southeast Asian countries' efforts to deliver safe, effective and accessible COVID-19 immunisation programs, based on a health and regulatory systems strengthening approach and in line with best practice standards.



Committed to safer use of medicines worldwide

ISoP 2021 Annual Meeting







Regulatory Agencies working together

- Spectrum from Transactional <----> Partnership
- Carrying out regulatory work on behalf of another agency: laboratory testing
- Information Sharing: unredacted evaluation reports; other review documents
- Knowledge Transfer: training webinars; communicating emerging safety information
- Adapting "best practices": development and use of evaluation templates.
- Capacity building: on-the-job training in a variety of regulatory functions
- Enabling Reliance: bilateral, product specific worksharing; multilateral approaches (ASEAN-JACG, WHO EUL)





Barriers to cooperation / reliance

- Differing priorities
- Confidentiality
- Timezones
- RMP evaluations:
 - differing focus areas
 - differing evaluator expertise
 - differing evaluation timelines (point at which RMP is considered)





Acknowledgements

- Dr Paul Huleatt
- Dr Shabnam Sharan
- Ms Liv Cocks



References

- Access: https://www.tga.gov.au/australia-canada-singapore-switzerland-united-kingdom-access-consortium
- ICMRA: https://www.icmra.info/drupal/
- ORBIS: https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis



Relying on combined global, regional and country information in Pharmacovigilance

November 8 3A-1

Merci de votre attention
Agradecimentos para sua atenção
Thank you for your attention
спасибо за Ваше внимание
ध्यान देने के लिए आपको धन्यवाद
ለሰጥህው አትኩሮት ሕናምስግናለን
תודה לך על תשומת הלב

